1.Epidemiological study of hepatitis B in 1990-2003 in Wuxi City, Jiangsu Province.
Chinese Journal of Epidemiology 2004;25(12):1083-1083
Adolescent
;
Adult
;
China
;
epidemiology
;
Female
;
Hepatitis B
;
epidemiology
;
prevention & control
;
Hepatitis B Vaccines
;
immunology
;
Humans
;
Incidence
;
Male
;
Vaccination
2.Etiological and molecular characteristics of pandemic influenza A (H1N1) virus during 2009-2010 in Shandong Province.
Ti LIU ; Yi LIN ; Sheng-Yang ZHANG ; Shuang WANG ; Yu-Yan YIN ; Zhong LI ; Xian-Jun WANG ; Ai-Qiang XU ; Zhen-Qiang BI
Chinese Journal of Virology 2011;27(3):224-230
To isolate and identify the influenza virus in Shandong Province in 2009-2010 and analyze the genetic characteristics of hemagglutinin and neuraminidase gene, further study the variation of gene. A total of 17 126 nasopharyngeal swabs from fever patients were collected and detected by real time quantitative RT-PCR method. The results showed 4004 samples were pandemic influenza A (H1N1) virus positive, with an overall positive rate as 23.38%. The positive samples were incubated and cultured in MDCK cells. The HA and NA genes of isolated pandemic influenza A(H1N1) virus were sequenced, the homology analysis of the HA and NA genes showed an average of 96.9%-99.3% and 99.1%-99.6% sequence identity, respectively, compared with WHO-recommended vaccine strain. The genetic evolution and amino acid substitutions were performed with Mega 4.0 Software. Twenty one amino acids were changed in HA protein, of which 11 were located in the antigenic site; Sixteen amino acids were changed in NA protein, which didn't lead to the changes of enzyme sites. Furthermore, one glycosylation site of HA protein and NA protein were changed respectively. No H275Y mutation in NA protein was found. The results showed that the HA and NA genes of the epidemic strains were highly homologous, some mutations in the HA and NA proteins were found, the antigenic site and glycosylation site of some strains were changed during the epidemic process. All the strains were sensitive to oseltamivir.
China
;
epidemiology
;
Hemagglutinin Glycoproteins, Influenza Virus
;
chemistry
;
Humans
;
Influenza A Virus, H1N1 Subtype
;
genetics
;
isolation & purification
;
Influenza, Human
;
epidemiology
;
virology
;
Neuraminidase
;
genetics
;
Pandemics
;
Phylogeny
;
Time Factors
3.Current Status and Growth of Nuclear Theranostics in Singapore
Hian Liang HUANG ; Aaron Kian Ti TONG ; Sue Ping THANG ; Sean Xuexian YAN ; Winnie Wing Chuen LAM ; Kelvin Siu Hoong LOKE ; Charlene Yu Lin TANG ; Lenith Tai Jit CHENG ; Gideon Su Kai OOI ; Han Chung LOW ; Butch Maulion MAGSOMBOL ; Wei Ying THAM ; Charles Xian Yang GOH ; Colin Jingxian TAN ; Yiu Ming KHOR ; Sumbul ZAHEER ; Pushan BHARADWAJ ; Wanying XIE ; David Chee Eng NG
Korean Journal of Nuclear Medicine 2019;53(2):96-101
The concept of theranostics, where individual patient-level biological information is used to choose the optimal therapy for that individual, has become more popular in the modern era of ‘personalised’ medicine. With the growth of theranostics, nuclear medicine as a specialty is uniquely poised to grow along with the ever-increasing number of concepts combining imaging and therapy. This special report summarises the status and growth of Theranostic Nuclear Medicine in Singapore.We will cover our experience with the use of radioiodine, radioiodinated metaiodobenzylguanidine, peptide receptor radionuclide therapy, prostate specific membrane antigen radioligand therapy, radium-223 and yttrium-90 selective internal radiation therapy.We also include a section on our radiopharmacy laboratory, crucial to our implementation of theranostic principles. Radionuclide theranostics has seen tremendous growth and we hope to be able to grow alongside to continue to serve the patients in Singapore and in the region.
Hope
;
Humans
;
Lutetium
;
Membranes
;
Nuclear Medicine
;
Prostate
;
Radium
;
Receptors, Peptide
;
Singapore
;
Theranostic Nanomedicine
;
Yttrium
4.Current Status and Growth of Nuclear Theranostics in Singapore
Hian Liang HUANG ; Aaron Kian Ti TONG ; Sue Ping THANG ; Sean Xuexian YAN ; Winnie Wing Chuen LAM ; Kelvin Siu Hoong LOKE ; Charlene Yu Lin TANG ; Lenith Tai Jit CHENG ; Gideon Su Kai OOI ; Han Chung LOW ; Butch Maulion MAGSOMBOL ; Wei Ying THAM ; Charles Xian Yang GOH ; Colin Jingxian TAN ; Yiu Ming KHOR ; Sumbul ZAHEER ; Pushan BHARADWAJ ; Wanying XIE ; David Chee Eng NG
Korean Journal of Nuclear Medicine 2019;53(2):96-101
The concept of theranostics, where individual patient-level biological information is used to choose the optimal therapy for that individual, has become more popular in the modern era of ‘personalised’ medicine. With the growth of theranostics, nuclear medicine as a specialty is uniquely poised to grow along with the ever-increasing number of concepts combining imaging and therapy. This special report summarises the status and growth of Theranostic Nuclear Medicine in Singapore.We will cover our experience with the use of radioiodine, radioiodinated metaiodobenzylguanidine, peptide receptor radionuclide therapy, prostate specific membrane antigen radioligand therapy, radium-223 and yttrium-90 selective internal radiation therapy.We also include a section on our radiopharmacy laboratory, crucial to our implementation of theranostic principles. Radionuclide theranostics has seen tremendous growth and we hope to be able to grow alongside to continue to serve the patients in Singapore and in the region.
5.A retrospective controlled study of TACE-HAIC-targeted-immune quadruple therapy for intermediate and advanced-stage hepatocellular carcinoma.
Ling LI ; Jian HE ; Yi Xing XIE ; Xin Hui HUANG ; Xia Ti WENG ; Xin Ting PAN ; Yu Bing JIAO ; Hang Hai ZHENG ; Lin Bin QIU ; Wu Hua GUO
Chinese Journal of Hepatology 2022;30(9):939-946
Objective: To evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE)-hepatic arterial infusion chemotherapy (HAIC)-targeted-immune quadruple therapy in patients with intermediate and advanced-stage hepatocellular carcinoma (HCC). Methods: 101 patients with intermediate and advanced stage HCC were enrolled according to the inclusion and exclusion criteria, and then they were divided into a combination group and a control group. Patients in the combination group was treated with TACE-HAIC-targeted-immune quadruple therapy, while the control group was only treated with TACE therapy. The overall survival (OS), progression-free survival (PFS), and treatment-related adverse reactions were statistically analyzed in the two groups of patients. Statistical analysis was carried out by t-test, χ2 test, rank sum test, Kaplan-Meier curve, log-rank test, Cox regression (or proportional hazards model) analysis according to different data. Results: The tumor objective response rate and disease control rate as evaluated by mRECIST 1.1 criteria in the combination group were 80% and 94%, respectively, which were significantly higher than those in the control group, 41.2% (P<0.001) and 74.5% (P=0.007). The OS and PFS of the combination group were 15.6 months [95%CI 11.3-NA ] and 8.8 months [95%CI 6.9-12.0], respectively, which were significantly better than the control group at 6.1 months [95%CI 5.3-6.6] (P<0.001) and 3.2 months [95%CI 3.0-3.6] (P<0.001). Gastric ulcer incidence was significantly higher in the combination group (9/50, 18%) than that in the control group (2/51, 3.9%) (P=0.023). Conclusion TACE-HAIC-targeted-immune quadruple therapy is a more effective treatment mode for intermediate and advanced-stage HCC than TACE alone, and attention should be paid to the monitoring of target immune-related adverse reactions.
Humans
;
Carcinoma, Hepatocellular/pathology*
;
Chemoembolization, Therapeutic
;
Liver Neoplasms/pathology*
;
Retrospective Studies
;
Infusions, Intra-Arterial
;
Treatment Outcome